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Background: The incidence of neuroendocrine tumours (NET) has increased over the past three
decades. Hepatic metastases which occur in up to 75% of NET patients significantly worsen their
prognosis. New imaging techniques with increasing sensitivity enabling tumour detection at an early
stage have been developed. The treatment encompasses a panel of surgical and non-surgical modalities.
Methods: This article reviews the published literature related to management of hepatic neuroendocrine
metastases.
Results: Abdominal computer tomography, magnetic resonance tomography and somatostatin receptor
scintigraphy are widely accepted imaging modalities. Hepatic resection is the only potentially curative
treatment. Liver transplantation is justified in highly selected patients. Liver-directed interventional tech-
niques and locally ablative measures offer effective palliation. Promising novel therapeutic options
offering targeted approaches are under evaluation.
Conclusions: The treatment of neuroendocrine liver metastases still needs to be standardized. Man-
agement in centres of expertise should be strongly encouraged in order to enable a multidisciplinary
approach and personalized treatment. Development of molecular prognostic factors to select treatment
according to patient risk should be attempted.
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Introduction
Neuroendocrine tumours (NET) represent a heterogeneous
group of neoplasms with distinct morphological and biological
manifestations.1–5 They are defined as either non-functioning
tumours with symptoms related to mass effects and malignant
tumour disease or functioning tumours with specific hormones/
neuropeptides autonomously secreted in sufficient amounts
to induce specific clinical syndromes. A further hallmark of
the tumour cells is the ability to take up amine precursors
and/or express somatostatin receptors (SSTRs). Most common
anatomical sites of their origin are the gastrointestinal tract and
the bronchopulmonary system.2–11 Neuroendocrine tumours can
develop either in a sporadic form or as a component of inherited
endocrine tumour susceptibility syndromes such as multiple
endocrine neoplasia, von Hippel-Lindau (VHL) syndrome and
neurofibromatosis-type 1.12,13
Historically, NET have been considered as rare tumours
comprising approximately 0.5% of all malignant conditions.14,15
More recent series encompassing large prospective tumour regis-
tries, e.g. Surveillance, Epidemiology and End Results (SEER),
report on the linearly increasing overall incidence and changing
spectrum of NET manifestation over the past four decades.5,16–23
With a global incidence of approximately 5–7 cases per 100 000,
gastroenteropancreatic NET have the second highest prevalence of
all gastrointestinal cancers. However, it remains a matter of debate
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if an increased awareness of the disease, widespread use of
advanced diagnostic techniques or true changes in incidence are
responsible for these observations. Within the intestinal group,
rates for appendiceal NET have decreased whereas those for NET
localized within the stomach, small intestine and rectum have
increased.5,16–18 Women with both diabetes and a positive family
history for cancer have been shown to harbour an increased risk
for developing gastric NET.24 Conversely, NET patients have an
estimated risk of 22.4% to have a second malignant non-
neuroendocrine tumour, most often adenocarcinoma of the
small bowel.5
Survival rates differ between the anatomic tumour locations
being the worst for pancreatic tumours and more favourable
for tumours arising in the respiratory tract or in the appendix
and for localized rectal NET.5,16,25–29 Beside the site and size of
the primary tumour,30,31 proliferative activity and the mitotic
index,32 presence of distant metastases,5,19,33 age,16,30 and several
other factors, such as depth of tumour invasion,30 vascular and
lymphatic invasion,33 plasma chromogranin A concentration,34,35
urinary 5-hydroxyindoleacetic (5-HIAA) levels28 and cellular
atypia, all influence tumour prognosis32
In contrast to the traditional opinion that NET represent an
indolent disease, two large population-based studies from the
United States5 and the United Kingdom20 encompassing 13 715
and 4104 patients, respectively, disclosed a rather poor overall
5-year survival of 67.2% regardless of tumour location and 5.2–
57% when considering different histological subsets of digestive
NET. Of note, no survival improvement over the last three decades
could be registered in either survey. In 12.9% of the patients,
metastases are already detectable at the time of initial tumour
diagnosis5 and a substantial number of patients (5–10%) presents
with metastases and primary of unknown origin. Beside regional
lymph nodes, the liver is the predominant site of NET metastases.
Up to 75% of patients with small bowel NET and 30–85% of those
with tumours localized within the pancreas present with liver
metastases (LM) either at initial evaluation or during the course
of their disease (Fig. 1a–b).5,36,37 An additional 5–10% of NET
patients present with LM with unknown primary tumour site.
Based on the NET cases included in the SEER 9 registry data of
1977–2004, Yao and colleagues observed a significantly better sur-
vival rate in patients treated since 1988.21 The authors hypothesize
that implementation of octreotide in the management of NET in
1987 might have contributed to this development.
This review was performed to elucidate the prognostic impact
of LM in patients with neuroendocrine tumours and to address
the role of the large variety of treatment options now available.
Impact of liver metastases on prognosis of
neuroendocrine tumours
Hepatic metastases are the most powerful prognosticator of
survival in patients with NET regardless of the primary site.38
A 13–54% 5-year survival in historical cohorts of patients with
untreated neuroendocrine LM compared with 75–99% in those
free of hepatic deposits underlines the unique molecular genetics
of malignant NET and, at the same time, clearly delineates them
from their non-endocrine counterparts.13,31,39–41 For patients with
gastrinoma without LM a 95% survival at 20 years has been
reported in contrast to 15% 10-year survival in the presence of
diffuse metastatic bilobar hepatic involvement.42 A 5-year survival
in small bowel NET decreases from 60% to 70% in the absence of
LM to 50–60% if LM occur.5,31,43 Colorectal NET rarely present
with LM; however, once metastasized, 5-year survival is less than
30% compared with 75–88% in localized tumours.5,34,44 Progres-
sion of LM associated with manifestation of bone metastases, as
frequently seen in poorly differentiated tumours, accounts as
an indicator of a very aggressive disease. Not only the presence
of LM, but also the pattern of their distribution, is a crucial deter-
minant of prognosis.34,45–47 It is not unexpected that limited
hepatic tumour load, in general, amenable for treatment, is
associated with a favourable survival. Aside from the impact of
Figure 1 Intraoperative finding in a patient with a 1 cm in size ileal
neuroendocrine tumor, necrotic mesenterial lymph node metastases
(a), and bilobar liver metastases (b)
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treatment on the prognosis of patients with neuroendocrine
LM, it was postulated that the pattern of hepatic metastatic spread
corresponds to the diverse tumour biology.46,48,49
Beside rarity and heterogeneous biological features of NET, lack
of a uniform and generally adopted classification system burdens
a reliable prognostic estimation of the metastasized condition.
Supplementing the World Health Organization (WHO) classifi-
cation of NET50 and its further refinement,51 efforts were made to
introduce new staging and grading systems that would serve as a
clinical tool for risk and prognosis assessment of an individual
patient. The European Neuroendocrine Tumor Society (ENETS)
adopted the current tumour-node-metastasis (TNM) WHO clas-
sification and proposed a new grading system which considered
the mitotic count and Ki-67 index52–54 (Table 1). A United States
group introduced a new TNM staging system by incorporating
tumour size and depth of invasion to the T category.55–58
Clinical manifestations
Depending upon the degree of endocrine activity and the local
effects of hepatic tumour load, patients with metastasized NET
may stay asymptomatic for a longer time or develop incapacitat-
ing hormone-excess symptoms in terms of carcinoid syndrome
and/or local discomfort. Vague clinical symptoms often delay
diagnosis of LM particularly in those originating from non-
functioning tumours. Even in patients with extensive metastatic
hepatomegaly, hepatic malfunction and hepatic failure are seldom
seen.
With regard to morphologic manifestation of neuroendocrine
LM, in general, three growth types can be discriminated: single
metastasis of any size (type I); isolated metastatic bulk accom-
panied by smaller deposits, with both liver lobes always involved
(type II); and disseminated metastatic spread, with both liver
lobes always involved, a single lesion of varying size and virtually
no normal liver parenchyma (type III).46,59 The three growth
types reflect a different grade of aggressiveness of the disease and
overlap with the staging system for gastrointestinal NET encom-
passing the tumour grading categories G1–G3. While G1 and G2
tumours are considered to correspond to well-differentiated
NET of different level of aggressiveness, G3 tumours correspond
to a poorly differentiated neuroendocrine carcinoma that
follows a highly aggressive course.52,53 In accordance with this
hypothesis, Sutliff et al. determined three different growth
rates of untreated hepatic metastatic gastrinoma: 26% of their
patients demonstrated no growth over a 29-month mean obser-
vation period, 32% showed slow growth and 42% had a rapid
growth (>50% volume increase per month) over an 11-month
follow-up.49
Diagnosis
Biochemical diagnosis
Liver metastases may be the first manifestation of NET. To classify
the tumour tissue as neuroendocrine, both biochemistry and
specific imaging procedures are helpful.
The biochemical diagnosis of NET is based on the evaluation of
specific tumour markers. Plasma chromogranin A (CgA), one of
the acidic proteins stored within secretory granules of neuroen-
docrine cells and secreted by a large variety of NET, is a widely
accepted tumour marker with respect to diagnosis, prognosis and
monitoring of the treatment.60–63 Its sensitivity depends upon the
NET type and tumour burden. Patients with LM tend to have
significantly higher CgA concentrations than those without
metastases.64 False-positive results can be obtained with renal
insufficiency,65 hypergastrinemia per se or as a result of proton
pump inhibitor therapy, hepatic failure and inflammatory bowel
disease. The main urinary serotonin metabolite, 5-HIAA serves as
an additional sensitive tumour marker for diagnosis and follow-
up. It is increased in patients with LM of NET from the small
intestine or the pancreas. For detection of tumours with low
serotonin production or those lacking DOPA decarboxylase,
measurement of platelet and urine serotonin, respectively, has
been recommended, but it is not widely applied in clinical
practice.28,66,67 Of note, while a serotonin-rich diet may lead to a
false-positive urinary 5-HIAA concentration, the determination
of platelet serotonin will not.68 Other circulating non-specific
peptide markers for NET are synaptophysin, neuron-specific
enolase, pancreatic polypeptide, human chorionic gonadotropin,
parathyroid hormone-related protein or calcitonin. However,
all of them are of lower clinical relevance.69,70 In functioning
tumours, those hormones related to the specific syndrome, e.g.
Table 1 The ENETS criteria for assessing the prognosis of non-functioning (neuro)endocrine pancreatic tumours52–54,239,240
Biological
behaviour
WHO
classification
Metastases Invasion Histological
differentiation
Tumour
size
(cm)
Angioinvasion Ki-67 index
(%)
Mitotic
count
(10 HPF)
Benign (low risk) Group 1 - - Well differentiated 2 - 2 <2
Benign or low-
grade malignant
(intermediate risk)
Group 1 - - Well differentiated >2  2 <2
Low-grade malignant Group 2 + + Well differentiated usually >3 + 3–20 2–20
High-grade malignant Group 3 + + Poorly differentiated any + >20 >20
10 HPF: high power field = 2 mm2, at least 40 fields (at 40¥ magnification) evaluated in areas of highest mitotic density.
Ki-67 index determined with MIB1 antibody; % of 2000 tumour cells in areas of highest nuclear labelling.
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insulin, gastrin, glucagons or vasoactive intestinal polypeptide
should be determined.
Morphologic imaging
After its introduction in the 1990s, somatostatin receptor scintig-
raphy (SRS) has rapidly evolved as the gold-standard imaging
procedure for NET expressing somatostatin receptor subtype 2.
Beside the advantage of total-body imaging with the potential
of simultaneous visualization of the primary tumour and
metastatic deposits (Fig. 2), SRS offers the possibility to identify
those patients who might be candidates for somatostatin
receptor-based radiotherapy.71–73 The initially used somatostatin
analogue [indium -111 (111 In)-diethylene-triamine-penta-
acetic acid (DTPA)-D-Phe1]-octreotide (111 In-DTPAOC)
(Octreoscan®)74–77 has been replaced in several units for the
benefit of more sensitive and highly specific radiophar-
maceuticals such as 1,4,7,10-tetra-azacyclododedcan-4,7,10-
tricarboxy-methyl-1-yl-acetyl-D-Phe1(DOTA) Try3 -octreotide
(DOTATOC) and DOTA-1-Nal3-octreotide (DOTANOC) with
high affinity to SSTR-2 and SSTR-2, -3, and -5, respectively.78
Moreover, the labelling of DOTATOC or DOTANOC with the
positron emitter gallium-68(68 Ga) (68 Ga-DOTATOC or 68
Ga-DOTANOC) provides the option of positron emission tomog-
raphy (PET) imaging with a diagnostic sensitivity up to 30%
higher than achieved by standard scanning.79–82 Precise fusion of
functional 68 Ga-DOTATOC PET images with a morphologic
image modality, such as CT (68 Ga-DOTATOC PET/CT), facili-
tates additional information.83–87 For patients with NET showing
negative 68 Ga-DOTATOC or DOTANOC PET/CT results
or those with elevated plasma serotonin levels, serotonin
and catecholamine precursors 18 F-dihydroxy-phenyl-alanine
and 11 C-hydroxy-tryptophan, respectively, as tracers are
recommended.88–90 Moreover, it has been shown that SRS
frequently revised the primary tumour staging, detected tumour
recurrence after resection of LM at an earlier stage than standard
imaging in one-third of cases,91 and changed the clinical manage-
ment in 33–77% of NET patients.46,72 For the assessment of the
additional benefit of more sensitive 68 Ga-DOTATOC PET/CT
more clinical data are still needed.
Contrast-enhanced abdominal ultrasound and multiphasic
helical computed tomography (CT) serve as the standard initial
imaging procedures. Utilizing advanced CT protocols and fusion-
ing of CT with single positron emission tomography, a sensitivity
of 94–100% has been noted.74,92,93 As an alternative to CT, T2-
weighted magnetic resonance imaging (MRI) using gadolinium,
or in some institutions, mangafodipir trisodium as liver-specific
contrast agents is recommended for routine staging, assessment
of disease progression and monitoring of the therapy. MRI allows
reducing excessive radiation burden.94–96
Histopathology
The diagnostic workup of LM should encompass tissue acquisition
for histopathological examination, especially so, as the staging
of NET depends on markers of proliferation (Ki-67 and/or the
mitotic index) and histopathological evaluation of vascular or
neural invasiveness. Tumour staging predicts the prognosis and
tailors the therapeutic strategy59,97 particularly in patients who are
not candidates for complete resection. As the cytological diagnosis
of neuroendocrine carcinoma remains unreliable, a core needle
biopsy or a biopsy via a laparoscopic approach with the additional
option to assess perihepatic lymph nodes may be more useful.98
Recently, the group from Yale University introduced polymerase
chain reaction (PCR)-based measurement of CgA gene expression
as a promising new tool for detection of neuroendocrine tumour
cells in apparently normal lymph nodes or equivocal liver lesions.99
In a substantial number of patients with neuroendocrine LM,
palliative therapy is the only possible approach. Thus, quality-of-
life assessment at the initial diagnosis and throughout treatment is
recommended in order to balance the benefits and potential
side-effects of the therapy applied.100–103 Figure 3 illustrates
diagnostic evaluation and treatment decisions for patients with
well-differentiated neuroendocrine LM.
Treatment
The best strategy for treatment of neuroendocrine LM is still
poorly defined despite the existence of various guidelines59,100,104–107
and comprehensive reviews addressing this topic.97,108–114 This is in
part because of the lack of prospective studies comparing different
treatment modalities in homogenous cohorts of patients. Two
recent Cochrane reviews on the optimal management of LM origi-
nating from gastrointestinal NET revealed that no evidence for
optimal therapeutic strategies exists.115,116
Selection of patients for surgery with curative intent
Meticulous patient selection is the key issue in hepatic surgery
with the potential for cure. When selecting candidates for the
Figure 2 68Ga-DOTATOC PET/CT revealing bilobar liver metastases
and a neuroendocrine primary localized within the small bowel
(arrow). The spleen shows physiological radionuclide accumulation
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resectional approach, the following prerequisites should be
considered59,117: (i) well-differentiated NET (G1 or G2 status,
Table 1),118 (ii) reasonable performance status and degree of
comorbidities, (iii) exclusion of non-resectable extrahepatic
disease, (iv) possibility of R0 resection with a remnant functional
liver parenchyma of 30%, (v) absence of advanced stages of
carcinoid heart disease as increased central venous pressure can
trigger severe haemorrhage during liver surgery,109,119,120 (vi) if
indicated, cardiac valve surgery prior to hepatic resection in
patients with advanced stages of carcinoid heart disease,120 and
(vii) acceptable morbidity (<15%) and mortality (<1–1.5%) of
the anticipated procedure. Ideally, the primary tumour should
already be eliminated prior to liver surgery or considered as resec-
table synchronously with LM in selected patients suitable for
aggressive surgery.121–123 In cases of unknown primary at the time
of liver surgery, close post-operative follow-up with the aim of
identifying the primary location or in rare cases, ultimately clas-
sifying the resected hepatic disease as a primary of hepatic origin,
must be assured.
In centres dealing with neuroendocrine LM, not only advanced
skills in hepatic surgery but also special techniques to achieve
resectability in patients initially considered as technically unresec-
table, should be available. Three-dimensional (3D) imaging soft-
ware and 3D CT angiography have proved to be valuable for
visualization of biliary and vascular structures. In addition, these
techniques allow for the calculation of post-resectional liver
remnant during pre-operative planning. In those cases where the
projected liver remnant is below 30%, portal vein embolization
(PVE) or right portal vein ligation can be performed to induce
hypertrophy of the future hemiliver.117,121,124,125 In patients with
bilobar metastases requiring extended surgery, radiofrequency
ablation (RFA) or cryotherapy can be applied as an adjunct to liver
resection, most commonly contralaterally to the site of hepatec-
tomy.117,118 If complete tumour elimination is not feasible, two-
stage hepatectomy, either as a sole procedure or in combination
with PVE, may be an option in selected patients.126,127 After a
two-step surgical strategy in 19 patients with synchronous bilobar
LM of digestive NET, Belghiti and his group achieved a 5-year
overall and disease-free survival of 94% and 50%, respectively.128
Their strategy encompassed the primary tumour resection
and limited non-anatomical resection of the left liver lobe includ-
ing ligation of the right portal vein. After hypertrophy of the
Symptom, biochemistry (specific hormones, CgA), US±FNB, MRI
NET
LM + extrahepatic disease (EHD)
LM + resectable EHD LM + unresectable EHD
LM
TACE
PRRT
SIRT
LT
TACE
SIRT
PRRT
LT+REHD
Type III
Type III
Type II
Type II
Type I
Type I
CRR±RFA
TACE
RFA
PRRT
SIRT
LT
CRR±RFA
TACE
RFA
PRRT
SIRT
LT+REHD
Resection Resection
Type III
TAC+PRRT
RFA+PRRT
CRR+PRRT
PRRT
SIRT+PRRT
TACE+PRRT
RFA+PRRT
PRRT
SIRT+PRRT
TACE+PRRT
RFA+PRRT
CRR+PRRT
PRRT
SIRT+PRRT
Type IIType I Type IIIType IIType I
64Ga-DOTATOC PET/CT + criteria for assessing the prognosis
Figure 3 Evaluation and treatment decision for patients with well-differentiated neuroendocrine liver metastases47.
LM, liver metastases; CRR, cytoreductive resection; RFA, radiofrequency ablation; LT, liver transplantation; TACE, transcatheter arterial
chemoembolization; SIRT, selective internal radiotherapy; PRRT, peptide receptor radionuclide therapy; EHD, extrahepatic disease; REHD,
resection of extrahepatic disease; US, ultrasound; FNB, fine needle biopsy
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tumor-free left liver lobe, a right or extended right hepatectomy
was carried out.
Surgery
Management of the primary tumour in patients with LM
Ideally, the primary tumour, including regional and distal lymph
nodes, should be radically resected prior to treatment of LM.
This condition enables adequate immunohistological tumour
classification and grading, reliable assessment of resectional
margins and exploration of the abdominal cavity for additional
extrahepatic tumour manifestation.
Assuming the primary negatively influences survival in patients
with LM, surgery of the primary tumour has been recommended
even in the presence of unresectable LM.129–131 Apart from the
resection of the primary tumour, Ki-67 and age at diagnosis have
been identified as additional independent prognostic factors in
the presence of LM originating from mid-gut NET.132 Among 84
patients reviewed by Givi et al. the median survival time in the
group with resected primary was 159 months, in contrast to only
47 months in the unresected group.130 In patients with symptom-
atic non-functioning pancreatic NET and unresectable LM, Hung
et al. demonstrated a marked reduction of symptoms and a lower
rate of progression in those with resection of the primary com-
pared with the unresected cohort.131 In addition to the prognostic
and symptomatic benefit, primary tumour resection including
enlarged perihilar and mesenteric lymph nodes reduces the risk
of intestinal obstruction, portal vein obstruction and ischaemia,
as a result of encasement and compression of the mesenteric
root.109,133,134 For patients with unresectable LM who might be
candidates for somatostatin analogue treatment or hepatic artery
embolization, preventive cholecystectomy was suggested to limit
the risk of future cholecystolithiasis and ischaemic cholecystitis.109
Liver resection
The evaluation of the effectiveness of the surgical approach is
hindered by the limited number and heterogeneity of patients
reviewed, as well as by the lack of uniform terminology for the
completeness of hepatic surgery. The definition of complete and
potentially curative resection ranges from: R0 resection,46,124,135–137
complete resection without information on R status,138–141 removal
of all visible gross disease,142 resections performed in combination
with RFA121,143–145 and/or transarterial chemoembolization143 or
cryoablation144 or results after RFA treatment.144 For palliative
surgical procedures determinants such as R1 or R2 resections,
incomplete resections, resections with gross residual disease,
cytoreductive surgery, partial cytoreductive surgery, palliative
cytoreduction, debulking and debulking of at least 90% of the
hepatic tumour mass are applied.
There is common consent that radical surgery including resec-
tion of the primary tumour and liver metastases may prolong
survival and offer symptom control in patients with resectable
neuroendocrine LM. Hepatic resection should not be attempted
when only incomplete elimination of the metastatic disease is to
be expected.111,117 The only exception is in patients with incapaci-
tating symptoms as a result of functioning LM. In these patients,
debulking may improve symptoms and prolong survival.
Overall survival after hepatic resection has been reported in
46–86% at 5 years and 35–79% at 10 years (Table 2). These wide
ranges likely reflect diverse patient selection and the heterogeneity
of the underlying tumour biology. Median overall survival in
patients in whom hepatic resection was feasible ranged from a
median survival time that was not reached during a follow-up of
27 months139 up to 78 months145 compared with 27 months139 and
17 months145 in those with unresectable tumour burden. The
decision for liver surgery is hampered by a reported complete
resection (R0) rate of only 20–57%46,124,139,140,144,146 and a 5-year
local recurrence rate of up to 97% even when complete resection
has been achieved.91,124,137,138
The largest experience with hepatic surgery for neuroendo-
crine LM has been documented in the three series from the Mayo
Clinic.138,147,148 Of the 37 patients reported on in the initial series
in 1990, 17 (46%) underwent curative resection, whereas in 20
patients gross residual tumour remained. In the curative group,
75% of the patients were disease-free at a median follow-up of
19 months. In 16 patients undergoing palliative resection of
hormonally active tumours, complete relief of symptoms was
obtained in eight patients with a median duration of response of
6 months. One patient died post-operatively. Six patients had
incomplete relief of symptoms and in one patient the symptoms
remained unchanged. The authors suggested that curative
resection should be the mainstay of treatment for patients with
tumours amenable to complete elimination. They stressed that
refinement of radiological imaging is necessary in order to
further reduce the number of patients undergoing surgery with
pre-operatively understaged disease. Despite their inferior results
with palliative resections, they recommended debulking for
symptom relief, however, only if at least 90% of the metastatic
mass can be eliminated safely.147 In the subsequent report on the
cohort of 74 resected patients, some of them overlapping with
those considered in the initial series, curative resection was
obtained in 28 (37.8 %). The post-operative complication rate
was 24% and two deaths occurred (2.7%). Overall survival was
75% at 4 years, with no significant difference between the com-
pletely and incompletely resected patients. The median time to
recurrence was 19.3 months and symptomatic response was
achieved in 90% of patients.148 In the last series encompassing
170 surgically treated patients, the group attempted to define the
role of liver resection as the benchmark against increasingly
applied non-surgical treatment options.138 The 5-year overall sur-
vival was 61% with a median survival of 81 months in the entire
study population. Morbidity was documented in 14% and two
patients died post-operatively. In total 84% and 94% of the
patients developed tumour recurrence at 5 years and 10 years,
respectively, with a median time to recurrence of 21 months. In
the 44% of patients with complete tumour resection, the 5-year
recurrence was 76% with a median time to recurrence of 30
366 HPB
HPB 2010, 12, 361–379 © 2010 International Hepato-Pancreato-Biliary Association
Ta
b
le
2
R
es
ul
ts
of
liv
er
re
se
ct
io
n
fo
r
ne
ur
oe
nd
oc
rin
e
liv
er
m
et
as
ta
se
s:
a
re
vi
ew
of
th
e
re
ce
nt
se
rie
s
A
ut
ho
r
Ye
ar
P
at
ie
nt
s
(n
)
E
xt
en
t
o
f
re
se
ct
io
n
(n
)
O
ve
ra
ll
su
rv
iv
al
af
te
r
re
se
ct
io
n
S
ur
vi
va
la
ft
er
cu
ra
ti
ve
re
se
ct
io
n
To
ta
l
R
es
ec
te
d
C
ur
at
iv
e
(R
0)
P
al
lia
tiv
e
3
ye
ar
s
5
ye
ar
s
10
ye
ar
s
5
ye
ar
s
D
ou
ss
et
14
1
19
96
36
17
12
5
87
%
(2
-y
)
46
%
N
S
C
ha
m
b
er
la
in
47
20
00
85
34
15
19
83
%
76
%
85
%
O
S
G
ra
zi
14
6
20
00
28
19
16
3
N
S
93
%
(4
-y
)
79
%
N
S
P
as
ch
er
13
5
20
00
41
26
13
13
85
%
(2
-y
)
76
%
N
S
N
av
e1
36
20
01
31
31
10
21
N
S
47
%
86
%
O
S
Ja
ec
k1
21
20
01
13
13
N
S
N
S
91
%
68
%
(6
-y
)
N
S
Ya
o1
40
20
01
36
16
16
0
N
S
70
%
70
%
O
S
E
lia
s1
24
20
03
11
2
47
25
a,
b
17
71
%
35
%
74
%
O
S
66
%
D
FS
S
ar
m
ie
nt
o1
38
20
03
17
0
17
0
75
95
N
S
61
%
35
%
N
S
of
O
S
24
%
D
FS
N
or
to
n1
22
20
03
16
16
16
a
0
N
S
82
%
82
%
O
S
To
uz
io
s1
43
20
05
60
30
18
a
12
N
S
72
%
N
S
H
ou
se
14
5
20
06
31
26
26
a
0
84
%
65
%
65
%
O
S
M
us
un
ur
u1
44
20
06
48
13
9a
4
83
%
60
%
N
S
M
az
za
fe
rr
o1
69
20
07
36
36
36
0
N
S
85
%
59
%
85
%
O
S
34
%
D
FS
G
om
ez
13
7
20
07
18
18
15
3a
94
%
(2
-y
)
86
%
90
%
D
FS
La
nd
ry
15
0
20
08
54
23
7
16
a
10
0%
75
%
N
S
K
ia
nm
an
es
h1
28
20
08
23
c
19
19
0
94
%
(2
-y
)
94
%
79
%
(8
-y
)
94
%
50
%
D
FS
Fr
ill
in
g4
6
20
09
11
9
27
23
4a
94
%
94
%
85
%
10
0%
O
S
96
%
D
FS
a S
er
ie
s
in
w
hi
ch
re
se
ct
io
n
ha
s
b
ee
n
p
er
fo
rm
ed
in
co
m
b
in
at
io
n
w
ith
ad
d
iti
on
al
tr
ea
tm
en
t
m
od
al
iti
es
su
ch
as
R
FA
,
TA
C
E
,
cr
yo
th
er
ap
y,
or
yt
tr
iu
m
-9
0
m
ic
ro
sp
he
re
s.
b
In
cl
ud
ed
ar
e
al
so
p
at
ie
nt
s
w
ith
co
m
p
le
te
re
se
ct
io
n
of
p
er
ito
ne
al
ca
rc
in
om
at
os
is
w
ho
un
d
er
w
en
t
su
rg
er
y
fo
llo
w
ed
b
y
in
tr
ap
er
ito
ne
al
ch
em
ot
he
ra
p
y.
c O
nl
y
p
at
ie
nt
s
co
ns
id
er
ed
fo
r
2-
st
ep
su
rg
er
y.
D
FS
,
d
is
ea
se
-f
re
e
su
rv
iv
al
;
N
S
,
no
t
st
at
ed
;
O
S
,
ov
er
al
ls
ur
vi
va
l.
HPB 367
HPB 2010, 12, 361–379 © 2010 International Hepato-Pancreato-Biliary Association
months, compared with 91% and 16 months in the incompletely
resected group. Owing to the fact that virtually all patients devel-
oped disease recurrence, the authors considered hepatic surgery
for neuroendocrine LM as unlikely to be curative, however,
they consider it of benefit with regard to survival and symptom
relief.109,138 These discouraging results question the effectiveness
of surgery and call for consideration of adjunct therapies. The
role of adjuvant treatment after R0 resection is poorly assessed.
Adjuvant therapy with streptozotocin and 5-fluorouracil failed to
improve disease-free survival in patients with digestive NET.149
In the report of Elias et al., 36 out of 47 (77%) patients required
extrahepatic tumour resection at the time of hepatectomy.124 The
respective morbidity and mortality rates of 45% and 5% in this
series most likely reflected the extent of the procedures. Twelve
patients with hepatectomy and complete resection of peritoneal
carcinomatosis were offered immediate additional intra-
peritoneal chemotherapy. While at the time of the report the
authors considered this as a possible curative approach, they
revised their opinion in a later report, as only 10% of these
patients remained disease-free at 5 years after surgery.124
Pascher et al. reviewed 41 patients with LM (40.2%) from a
cohort of 102 NET patients seen during a 10-year period.135 In
90% of cases, LM were multifocal, and in 75%, additional extra-
hepatic disease was evident. Hepatic surgery marginally pro-
longed median survival to 60 months in the resected patients
compared with 46.5 months in the non-resected group. The prog-
nostic relevance of R0 resection has been pointed out by Gomez
et al.137 In their group of 18 resected patients, the overall 5-year
recurrence rate was 34%. Five-year recurrence was only 10% in
patients with tumour-free resection margins, in contrast to 75%
when resection margins were involved.
Effectiveness of surgical resection in comparison to hepatic
artery embolization and medical therapy was first studied by
Chamberlain et al. in a group of 85 patients with additional
extrahepatic disease in 38 of these patients.47 Three- and five-
year survival rates for the entire cohort were 61% and 53%,
respectively. Analysis of the three treatment groups yielded
3- and 5-year survivals for patients with surgery, hepatic artery
embolization or medical therapy of 83%, 83% and 39% and
76%, 50% and not available, respectively. Curative resection was
associated with prolonged survival; however, surgery was benefi-
cial only in patients with less than 75% tumorous liver involve-
ment. In the series of Yao et al. focusing on hepatic resection vs.
chemoembolization, the 5-year survival for the resected patients
was 70% whereas it dropped to 40% when chemoembolization
was performed.140
Touzios et al. compared survival in 60 patients with either
invasive [resection/ablation or transarterial chemoembolization
(TACE)  resection/ablation] or non-invasive (chemotherapy,
radiation, octreotide) treatment strategies. They found a signifi-
cantly better median and 5-year survival with invasive treatment
(>96 months and 72% for resection/ablation, 50 months and
50% for TACE  resection/ablation) then for non-invasive
therapy (20 months and 25%, respectively).143 However, invasive
treatment was beneficial only for those patients with less than 50%
liver involvement.
The preponderance of cytoreductive surgery over embolization
for symptomatic neuroendocrine LM has been documented by
Osborne et al.142 Of a total of 120 patients, those 61 patients who
underwent surgery had a mean duration of symptom relief of 32
months and mean survival of 43 months, as compared with 22
and 24 months, respectively, in the group with embolization
therapy. Based on their experience, these authors suggested
hepatic cytoreduction rather than embolization, even if complete
disease resection may not be feasible.
Other groups demonstrated benefits of surgical therapy, either
complete or cytoreductive, in comparison with (i) hepatic artery
embolization and medical treatment,144 (ii) medical therapy,133
and (iii) various liver-directed non-resectional interventions150 or,
in case of cytoreductive resection, as a component of a multimo-
dality approach including hepatic artery embolization, RFA,
chemotherapy and peptide receptor radionuclide therapy
(PRRT).150–153 Reduction of a CgA level of 80% was shown to
reliably indicate post-operative symptom relief and stabilization
of disease after cytoreductive surgery.154 For prolongation of
symptom-free survival, adjuvant treatment with octreotide
long-acting release was recommended.155
Liver transplantation
As a result of their less aggressive biological behaviour when com-
pared with other secondaries, non-resectable neuroendocrine
LM have been accepted as an indication for orthotopic liver trans-
plantation (OLT). Since the first reports in 1988 by O’Grady
et al.156 and Iwatsuki et al.157 on two and five transplanted patients,
data on approximately 170 transplanted patients have been
collected worldwide. Lack of stringent generally adopted pre-
transplant selection criteria and of uniform follow-up protocols
hamper critical assessment of the published results (Table 3).
In the initial series encompassing rather unselected
patients, overall and recurrence-free 5-year survival of 36–57%
and 24–45%, respectively, has been reached.141,158–162 Based on
their experience with nine transplanted patients, Dousset et al.
demonstrated for the first time that better patient selection, e.g.
removal of the primary tumour prior to OLT, with the option of
concomitant exclusion of extrahepatic tumour spread and car-
cinoid rather than non-carcinoid primaries, may contribute
to better treatment results.141 Bearing in mind the immanent
scarcity of donor organs and the potential risk of immuno-
suppression after transplantation for a oncological condition,
the same group further recommended considering patients with
rapid tumour growth unresponsive to alternative treatment
options rather than those with quiescent disease as transplant
candidates.163 The first multicentric study from France encom-
passing 31 patients confirmed significantly better survival for
carcinoid as opposed to non-carcinoid tumours (69% at 5 years
vs. 8% at 4 years).161 In a more recent multicentric report from
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the same group analysing 85 patients, duodenopancreatic
primary localization and extensive hepatic tumour load have
been suggested as factors indicating poor prognosis.164 While the
5-year survival rate was 68% in patients with limited hepatic
disease and non-duodenopancreatic tumours, it dropped to 12%
in the case of hepatomegaly and primary tumour localized
within the duodenum or pancreas. This has been confirmed by
other groups as well.165
The prognostic relevance of Ki-67 and E-cadherin, a marker for
cell proliferation and metastatic potential of tumours, respec-
tively, has been demonstrated by Rosenau and co-workers.166
In transplanted patients with Ki-67 5% and/or aberrant
E-cadherin, expression survival was significantly decreased com-
pared with those with lowed expression of Ki-67 and regular
E-cadherin staining results (7-year survival 0% vs. 100%, respec-
tively). The importance of Ki-67 as a selection criterion, in addi-
tion to the diagnosis of extrahepatic tumour spread prior to
transplantation by octreotide scintigraphy, has been pointed out
by several investigators.165,167,168 On the other hand, Olausson
et al. achieved an excellent 5-year overall survival and 1-year
recurrence-free survival of 70% despite expanding their criteria
for transplantation towards an older age (64 years) and higher
Ki-67 (10–15% in 6 of the 15 patients).168 In cases of NET local-
ized within the pancreatic head, the group followed a very
aggressive approach and removed the primary tumour, lymph
nodes and liver followed by multivisceral transplantation (liver,
stomach, pancreas, duodenum and upper third of the small bowel
or entire small bowel). The close post-transplant follow-up and
the aggressive treatment approach in case of tumour recurrence
(median time to recurrence of 1.9 years, recurrence-free survival
of 20% at 5-years) resulted in a 5-year overall survival of 90%,
despite the inclusion of some high-risk patients.
In our own experience in 17 patients transplanted for NET
LM, Ki-67, SRS-based exclusion of non-resectable extrahepatic
tumour manifestation and carcinoid heart disease proved to be a
particularly powerful selection criteria.46,167 The following criteria
for the indication for transplantation were identified by Mazza-
ferro et al.: functioning or non-functioning low-grade NET, a
primary tumour drained by the portal system and removed with a
curative resection preceding transplantation, 50% metastatic
involvement of the liver, good response or stable disease for a
minimum of 6 months prior to transplantation and age 50
years.169 After this policy they achieved a 90% overall survival and
a 77% recurrence-free survival at 5 years. In general the indication
for liver transplantation for metastatic NET has been considered
either as a curative treatment option or as palliation for patients
with intractable symptoms.59,165,167,168,170 The group from Milan, in
contrast, demanded a 5-year recurrence-free survival of at least
50% as a benchmark to justify the intervention. Further develop-
ments are the recommendation of living donor liver transplanta-
tion for neuroendocrine tumour patients to spare the deceased
donor pool for patients with benign indications.164,165,167,170,171
A critical review of the data on surgical treatment of neuroen-
docrine LM is burdened by the small number of patients eligible,
Table 3 Summary of results of liver transplantation for hepatic metastases of neuroendocrine tumours
Author Year Patients
(n)
Overall survival Disease free survival
1-year 3-years 5-years 3-years 5-years
Makowka242 1989 5 60% NS NS NS NS
Curtiss247 1995 3 100% NS NS NS NS
Anthuber245 1996 4 25% 0 0 0 0
Pascher135 2000 4 100% NS 50% NS NS
Ringe244 2001 5 74% 56% NS 31% NS
Rosenau166 2002 19 89% 89% 80% 35% 8%
Amarapurkar243 2003 14 64% 50% 14% 25% 12%
Fernandez246 2003 5 80% 80% (2-y) NS 40% (2-y) NS
Florman170 2004 11 73% NS 36% NS NS
van Vilsteren165 2006 19 88% NS NS 80% (1-y) NS
Frilling167 2006 15 78% NS 67% 48% (2-y) 48%
Mazzaferro169 2007 24 NS NS 90% NS 77%
Marin241 2007 10 86% 57% NS 38% NS
Olausson168 2007 15a NS NS 90% 70% (1-y) 20%
Le Treut164 2008 85b 72% 59% 47% 37% 20%
In order to avoid data overlap, only the most recent report of an institution is considered.
aIncludes five multivisceral transplantations.
bMulticentric study.
NS, not stated.
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the different prognoses of pancreatic and mid-gut tumours and
the lack of data from prospective studies.
Locally Ablative Techniques
Radiofrequency ablation
Radiofrequency ablation can be used as an image-guided percu-
taneous procedure, laparoscopically or through an open surgical
approach, either as a single procedure or in combination with
other techniques.172,173 The method is amenable to repeated appli-
cations. Evidence exists that laparoscopic and open techniques
provide superior local tumour control compared with percutane-
ous approaches, regardless of the size of the lesion.174,175 In the
largest series on RFA in neuroendocrine LM, Mazzaglia et al.
treated 452 liver lesions laparoscopically in 63 patients.176 The
mean number of lesions treated at the first RFA session was six
(range, 1–16) and mean tumour size was 2.3 cm (range, 0.5–
10 cm). The procedure-associated morbidity was 5% and there
was no 30-day mortality. Median survival was 3.9 years calculated
from the first RFA session. On multivariate analysis, gender and
the size of the dominant LM were predictive of survival. Median
survival was most favourable in patients with a diameter of the
dominant liver lesions of <3 cm. The lowest local recurrence
among different primary and secondary liver tumours was
achieved in neuroendocrine LM with <3 cm and at least a 1-cm
circumferential post-ablation margin.177 In a separate study, the
Cleveland group showed that RFA is associated with an increased
risk of liver abscess formation in patients with a previous Whipple
procedure (40% vs. 0.4%) as a result of the colonization of the
bile duct system. This finding might be important for surgical
candidates with pancreatic NET.178
Hellman et al. performed RFA percutaneously or intra-
operatively in 21 patients with endocrine tumours and 43 LM.153
At a mean follow-up of 2.1 years (range, 3 months–4 years),
complete tumour ablation was documented in 96% of the
tumours. Post-interventional bile leakage and pleural effusion
accompanied by fever were seen in one patient each. In a group of
25 patients with 189 neuroendocrine LM, Gillams et al. performed
30 and 36 percutaneous treatment sessions with a solid-state laser
and RFA, respectively.179 At a median follow-up of 21 months
(range, 4–75 months) local tumour control and symptom relief
were evident in 75% and 69% of patients, respectively. Wessels and
Schell successfully applied RFA as salvage treatment for carcinoid
hepatic metastases refractory to hepatic artery embolization.180
Other locally ablative measures, such as laser therapy,181
cryotherapy182–184 and ethanol injection,173,185 successfully achieved
symptom control and positive tumour response in smaller case
studies. However, they were gradually replaced by RFA in most
centres because of better treatment results. Using cryotherapy in
13 patients with 52 neuroendocrine LM, Seifert et al. documented
a treatment response in all seven symptomatic patients.186 Of note,
however, was a morbidity rate of 31% encompassing bleeding
caused by coagulopathy, acute renal failure and pulmonary embo-
lism. The well-recognized problem of an increased risk of haem-
orrhage related to large-diameter probes might be resolved by the
newly developed small-caliber probes.113 Ethanol injection under
ultrasound guidance has been shown to be useful in selected
patients with smaller lesions adjacent to biliary or vascular struc-
tures vulnerable to the heat-sink effect.173,187 Recently introduced
microwave coagulation therapy utilizing electromagnetic micro-
waves, which agitate water molecules in the surrounding tumour
tissue causing cellular death through coagulation necrosis, may be
superior to RFA in cases when ablation of larger and/or multifocal
tumours is attempted.188
Percutaneous liver-directed techniques
Hepatic transcatheter arterial embolization and
transcatheter arterial chemoembolization
Induction of a selective ischaemic necrosis after surgical ligation
or transient occlusion of the hepatic artery accounts for the initial
vascular occlusive therapy for palliation of symptomatic patients
with metastatic NET.189 Utilizing this concept hepatic trans-
catheter arterial embolization (TAE)190,191 and transcatheter arte-
rial chemoembolization (TACE)192 have been consecutively
introduced. Although both techniques have been widely adopted,
it remains debatable if the addition of cytotoxic drugs to embo-
lization material increases the effectiveness of bland embolization
alone, particularly when performed selectively.113,172,193–197 In a
multicentric retrospective review on 100 patients treated with
either TAE or TACE, Pitt et al. revealed no difference between the
two techniques with regard to median overall survival, symptom
improvement, morbidity and mortality. Controversies exist
regarding the extent of liver volume that should be embolized
during a single treatment session, the effectiveness of different
chemotherapeutic regimens, the timing of the procedure during
the course of the disease (‘early’ vs. ‘late’ embolization) and
the timing of subsequent embolization procedures. A post-
embolization syndrome, i.e. transient fever, abdominal pain and
elevation of liver enzymes, is frequently seen. Portal vein throm-
bosis and hepatic insufficiency are considered exclusion criteria
for both TAE and TACE.198,199
In one of the largest single-centre studies including 69 patients
with carcinoid tumours and 54 patients with pancreatic neuroen-
docrine carcinoma, Gupta et al. identified prognostic factors for
progression-free survival after TAE or TACE.200 Comparing the
results of patients with carcinoid tumours vs. those with pancre-
atic NET, patients with carcinoid tumours had a longer overall
cumulative survival at 2 and 5 years (68.6% and 28.6% vs. 48.7%
and 13.7%, respectively), better radiological response rate (66.7%
vs. 35.2%) and longer median progression-free survival (22.7
months vs. 16.1 months). Male gender was the only independent
risk factor for unfavourable survival in carcinoid patients. A per-
sistent primary tumour, 75% liver involvement and bone
metastases were predictive for poor survival in patients with pan-
creatic NET. While in the carcinoid group, TAE was associated
with a significantly higher response rate than TACE, no such
difference was obvious for pancreatic NET. Post-embolization
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syndrome occurred in nearly all cases and major complications
were documented in 19 patients, of them most with large-volume
liver involvement. Interestingly, the difference between the
patients with carcinoids and those with islet cell tumours after
treatment with TAE or TACE was not confirmed by Ho et al.201
Among the 122 patients with metastasized carcinoids treated with
TACE by Bloomston et al. peri-interventional morbidity and
mortality were seen in 23% and 5%, respectively.202 A radiographic
tumour response was documented in 82%, accompanied with
disease stabilization in 12%. Symptom palliation with a median
duration of 13 months was achieved in 92% of the patients. In a
most recent review on interventional treatment of neuroendo-
crine LM, Vogl et al. recommended TAE or TACE for patients with
multifocal disease and higher tumour burden, whereas surgical
resection or local ablative are preferred techniques for those with
single metastatic deposits.203
Radioembolization
Selective internal radiation therapy (SIRT), combining the effect
of interstitial high-dose radiation and embolization of malignant
microvasculature with micro spheres, has evolved as a promising
treatment option for hepatic malignancies, among them also neu-
roendocrine metastases.204–206 In a retrospective multicentric study
on 148 patients with LM of various NET treated with yttrium-90
(90Y) labelled resin microspheres, a complete or partial response
on imaging studies was seen in 2.7% and 60.5% of patients,
respectively. Stable or progressive disease was documented in
22.7% and 4.9%, respectively. The median survival time was 70
months. The authors concluded that SIRT has the potential to
deliver high doses of radiation to neuroendocrine LM, yielding a
treatment effect and safety profile comparable to other local tech-
niques. King et al. combined SIRT with a 7-day systemic infusion
of 5-fluorouracil (5-FU) in 34 patients with unresectable
neuroendocrine LM, of them 59% with additional extrahepatic
disease. They achieved a radiological response in 50% of cases,
with 18% and 32% showing a complete or partial response,
respectively.207 A symptomatic response accompanied by a
decrease of the CgA serum concentration was seen in 55% and
50% of the patients at 3 and 6 months, respectively. The mean
survival was 27.6 2.3 months. The number of treatment-related
side-effects was low. As an alternative to SIRT, selective hepatic
arterial administration of radionuclide-labelled somatostatin
analogues were shown to provide radiological tumour response
and symptomatic relief in single patients with large-volume
somatostatin receptor positive LM.208,209
The time line for palliative non-surgical strategies, i.e. before or
after systemic therapy remains unclear. Treatment strategies have
to be individualized according to experience, patient preference
and quality of life considerations.
Systemic treatment options
Peptide receptor radionuclide therapy
The peptide receptor radionuclide therapy (PRRT), a
somatostatin-analogue-based targeted therapy, is an emerging
new field in the palliative treatment of NET with very encouraging
data. The treatment modality utilizes radioactive substances that
are conjugated with various somatostatin analogues such as oct-
reotide or lanreotide. Intravenously administrated, these drugs
bind to the somatostatin receptor localized on the tumour cells.
The ligand–receptor complex is internalized and the attached
radiation has the potential to destroy the tumour cells.107,210 The
side-effects are few and mostly mild, in particularly when treat-
ment protocols consider renal protective agents. Initially used
111In-DTPA-[D-Phe1]-octreotide achieved partial remission
rates up to 8%, whereas stable disease was seen in 42% to 81% of
patients.101,211–213 Despite these positive results, it has been recog-
nized early that because of the limited tissue penetration range of
111In, 111In-coupled peptides are rather ineffective for PRRT and
their utilization should be restricted for therapeutic purposes.
More suitable somatostatin analogues such as DOTATOC and
[DOTA,Tyr3]octreotate (DOTATATE)] labelled with 90Y or
lutetium-177 (177Lu) achieved better results in terms of response
and imaging-assessable tumour mass reduction. Another
approach, using the more lipophilic somatostatin analogue lan-
reotide (90Y-DOTA-lanreotide, DOTALAN) induced disease
regression in 14% and stable tumour disease in 41% of patients.214
In various studies with 90Y-DOTATOC in metastasized intestinal
NET using different protocols, the overall response rate varied
between 24% and 33%.215–218 In our own experience with 90Y- and
177Lu-DOTATOC treatment in 20 patients with metastasized
NET, all with LM, partial remission or stable disease were achieved
in 5 and 11 patients, respectively, while tumour progression was
documented in four patients.152 In a recent study from Rotterdam
on 177Lu-DOTATATE in 310 patients with intestinal NET,
tumour response of various degrees was found in 46%, stable
disease was seen in 35% and progressive disease in 20%.219
Chemotherapy
The efficacy of systemic cytotoxic therapy, traditionally based on
streptozotocin in combination with 5-FU or doxorubicin, in well-
differentiated mid-gut NET is low, yielding response rates of not
more than 10–15%.122–124 In contrast, pancreatic NET trials of
streptozotocin plus 5-FU/doxorubicin or dacarbazine as a mono-
agent demonstrated objective tumour response rates of 39% and
33%, respectively, and an improved overall survival.220,221 Using
temozolomide and thalidomide Kulke et al. achieved a response
rate of 45% in pancreatic NET, but only 7% in mid-gut NET.222
Patients with poorly differentiated NET, regardless of the primary
tumour localization, are candidates for cisplatin and etoposide
treatment. Response rates of 55–80% are reported, with a median
duration of response of 8–11 months.223
Biotherapy and antiproloferative therapy
Biotherapy with somatostatin analogues or alpha interferon
and, more recently, antiproliferative therapy with tyrosine kinase
inhibitors, anti-angiogenic substances and mammalian target of
rapamycin (mTOR) inhibitors, have been implemented as sys-
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temic treatment in NET.224–226 Somatostatin analogues, either as
single agents or rarely in combination with interferon, effectively
relieved symptoms of functional tumour disease.227–231 Recently,
the PROMID study comparing somatostatin analogue octreotide
long-acting repeatable (LAR) vs. placebo in patients with well-
differentiated mid-gut NET reported a significantly increased
median time to progression (14.4 vs. 6 months, respectively).232
The ability of NET to express vascular endothelial growth factor
(VEGF) and its receptor (VEGFR) make them suitable candidates
for novel therapeutic strategies based on anti-angiogenic agents.233
A recent trial of sunitinib, a tyrosine kinase inhibitor with activity
against various receptors, among them VEGFRs, reported a 16.7%
overall response rate and 68% stable disease in pancreatic NET
patients compared with 2.4% and 83% for non-pancreatic NET.234
In a phase II study, in which 44 patients on stable doses of
octreotide were treated either with VEGF antibody bevacizumab
or pegylated interferon alpha-2b, bevacizumab treatment was
associated with an objective tumour response, reduction of
tumour blood flow and longer progression-free survival when
compared with the alternative treatment arm.235 mTOR is a serine/
threonine kinase involved in cell cycle, cell proliferation and
angiogenesis. Its inhibitor, RAD001 (everolimus) alone or in
combination with octreotide LAR has generated a partial response
in 22% of patients with low-to intermediate-grade NET with
stabilization of the disease in 70% of patients.236
Follow-up
Imaging studies with ultrasound, CT, MRI, SRS, in addition to
repeated determination of the tumour marker CgA, are used for
the follow-up of patients with neuroendocrine LM. In functioning
tumours’ cases, tumour-specific hormones are used. For poorly
differentiated NET, neurospecific enolase serves as an additional
useful marker. The time frame for follow-up is individualized,
depending on the different tumour subtypes, the grade of differ-
entiation and the treatment performed. Patients with G1 and G2
tumours should be followed every 6–12 months and 6 months,
respectively, whereas for G3 tumours 3-months intervals are
recommended.237
Conclusions
The number of neuroendocrine tumours seen in a clinical practice
is continuously increasing. An as yet unanswered question is
whether this represents a true increase of biological incidence or is
an increase because of our growing percipience of the disease.
Hepatic metastases, which frequently occur in NET patients, sig-
nificantly worsen their prognosis. While little progress in the treat-
ment was achieved in the past, new specific imaging techniques
with increasing sensitivity enabling tumour detection at an early
stage and promising novel therapeutic options offering targeted
approaches are under evaluation. Management in centres of
expertise should be strongly encouraged in order to appropriately
assess and classify the tumour burden and provide personalized
multimodal treatment.238
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